Tom Knight, founder of Optinosis, a maker of AI-enabled tools for early disease detection, will lead the organization as CEO. Knight will guide the early stage startup as it builds healthcare solutions to detect diseases like cancer earlier, with a goal of improving outcomes and lowering overall cost of care for patients and health plans.
Knight, who holds a master’s degree in engineering and an MBA from the Massachusetts Institute of Technology (MIT), most recently founded and led Invistics, a U.S.-based provider of AI-enabled drug diversion detection software, which was acquired by Wolters Kluwer in 2023. His career has focused on leveraging AI to solve challenges across sectors, including healthcare, manufacturing and supply chain.
“AI and preventative care are poised to radically disrupt the healthcare industry, but it will take the right tools and leadership to build effective solutions that align all stakeholders,” said Sig Mosley, chairman of Optinosis’ board and serial technology investor. “Tom has a long history of creating the right teams and strategically scaling operations to solve some of healthcare’s most pressing challenges, and I have no doubt he’ll lead Optinosis with the same passion and expertise he’s applied throughout his career.”
The National Institutes of Health (NIH) reports that nearly four in ten Americans will be diagnosed with cancer in their lifetimes. Optinosis will help providers detect common cancers earlier by using AI to analyze existing patient health records. This early detection will give patients stronger prognoses while lowering the overall cost of cancer care for Medicare Advantage and other health plans.
“Cancer is the second-highest cause of death in the United States and is a major expenditure across our healthcare ecosystem. Early detection and treatment is literally a matter of life and death,” Knight said. “Optinosis can use existing data within a healthcare record to more quickly determine if a patient is at-risk. Our tools will help countless Americans live better, longer lives while alleviating financial pressures for Medicare Advantage and other health plans as they pay increasingly more to treat cancers in our country.”
About Optinosis™
Optinosis builds AI-enabled healthcare solutions that detect diseases earlier and reduce the cost of patient care. Leveraging the power of AI, Optinosis uncovers new insights and risk factors within existing patient health records and other data sources. Optinosis solutions can more quickly and accurately detect potential life-threatening diseases, like cancers, to improve patient outcomes, while simultaneously reducing costs for Medicare Advantage health plans. Learn more about Optinosis or contact info@optinosis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030515669/en/